Primary pericardial mesothelioma

Santos, Cristina; Montesinos, J.; Castañer, Eva; Solé, Josep María Macias i; Bagà, Rosa

doi:10.1016/j.lungcan.2007.08.029

Cited by 39 publications

(30 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the introduction of pemetrexed, a third-generation antifolate drug, demonstrated a survival benefit when combined with cisplatin in patients with pleural mesothelioma (23), leading to longer survival times for patients with PMPM. In previous cases, several patients who were treated with pemetrexed plus carboplatin or pemetrexed plus cisplatin demonstrated positive responses after receiving only two or three cycles of pemetrexed plus platinum (14,24,25). Following 6-8 cycles of treatment, chemotherapy was stopped or consolidation radiotherapy was added in these cases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report

et al. 2016

View full text Add to dashboard Cite

Abstract. Primary malignant pericardial mesothelioma (PMPM) is a rare tumor with poor prognosis. Surgery is the treatment of choice, but numerous cases are inoperable. For the treatment of inoperable or metastatic cases, systemic chemotherapy is required. However, a standard chemotherapeutic regimen for the treatment of pericardial mesothelioma has not yet been established. Chemotherapy involving pemetrexed and cisplatin has been actively used in the treatment of pleural or peritoneal mesothelioma, and may be considered for the treatment of PMPM. The present study reports the case of a patient with PMPM with lung metastasis who demonstrated a positive response to treatment with pemetrexed and cisplatin followed by pemetrexed maintenance chemotherapy, leading to prolonged progression-free survival for 21 months.

show abstract

Section: Discussionmentioning

confidence: 99%

“…to disease progression (24,25). In patients in whom the response to chemotherapy is positive, it is difficult to determine the appropriate duration of chemotherapy.…”

Section: A B Cmentioning

confidence: 99%

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Primary malignant pericardial mesothelioma accounts for 2-3% of all primary cardiac tumors and less than 1% of all mesotheliomas [2]. However, about 50% of primary pericardial tumors are mesotheliomas [3]. In autopsy series, the incidence of mesothelioma was reported to be very low, 0.0022% [4].…”

Section: Discussionmentioning

confidence: 99%

“…Drugs such as doxorubicin, vincristine and cyclophosphamide have limited single agent activity and may reduce the tumor burden [10]. A platinum drug with gemcitabine, raltirexed or pemetrexed might be options but at this time point, combination of a platinum drug with pemetrexed is the standard of care for pleural disease [3]. In a case reported from Japan, cisplatin with gemcitabine, and vinorelbine was shown to provide a 2 year progression-free survival [11].…”

Section: Discussionmentioning

confidence: 99%

Primary pericardial malignant mesothelioma: A rare but aggressive disease

Arslan¹

2012

CMJ

View full text Add to dashboard Cite

Malignant mesothelioma of the pericardium is a rare disorder with a worse outcome compared to the pleural presentation of the disease. All treatment modalities are usually palliative. Here we report a patient with malignant mesothelioma of the pericardium presenting with severe dyspnea and pericardial effusion who survived only 2 months despite aggressive treatment. Keywords: Malign mesothelioma, pericardium, chemotherapy ÖzetMalign perikardiyal mezotelyoma plevral mezotelyoma ile karşılaştırıldığında nadir ve daha kötü seyirli bir hastalıktır. Tüm tedavi uygulamaları genellikle palyatif kalmaktadır. Bu makalede ciddi dispne ve perikardiyal effüzyon ile seyreden ve agresif tedaviye rağmen sadece 2 ay yaşayabilen bir malign perikardiyal mezotelyoma olgusu sunulmaktadır. Anahtar sözcükler: Malign mezotelyoma, perikard, kemoterapi Geliş tarihi

show abstract

“…Primary malignant pericardial mesothelioma (PMPM) is extremely rare, with an incidence of <0.0022% and a poor prognosis, with a survival from the onset of symptoms of <6 months (1). Unlike pleural and peritoneal mesothelioma, the association between exposure to asbestos and PMPM remains controversial (2).…”

Section: Introductionmentioning

confidence: 99%

Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report

Kurosawa

Sugino

Isobe

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.A 37-year-old female smoker without a history of exposure to asbestos was referred to our hospital with persistent pericardial effusion. Chest computed tomography imaging examination revealed an irregular thickened pericardium with large amounts of pericardial effusion and a small pleural effusion. Fluorodeoxyglucose (FDG) positron emission tomography imaging demonstrated intrapericardial FDG accumulation. Blood tests revealed an increase in serum mesothelin levels. Examination of a surgically resected specimen revealed a grayish-white thickening of the pericardium, with a straw-colored mucinous pericardial effusion. Histopathological examination confirmed the diagnosis of epithelioid malignant mesothelioma. Although the patient's condition temporarily improved, with decreased levels of serum mesothelin during chemotherapy with carboplatin and pemetrexed, she succumbed to cardiac tamponade 18 months after the initial onset of the symptoms. Primary malignant pericardial mesothelioma (PMPM) is an extremely rare and refractory disorder. Thus, an early definitive diagnosis and timely treatment are crucial for the management of PMPM.

show abstract

Primary pericardial mesothelioma

Cited by 39 publications

References 3 publications

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report

Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report

Primary pericardial malignant mesothelioma: A rare but aggressive disease

Primary malignant pericardial mesothelioma with increased serum mesothelin diagnosed by surgical pericardial resection: A case report

Contact Info

Product

Resources

About